These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 20965983)
1. Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective. De Filette M; Ysenbaert T; Roose K; Schotsaert M; Roels S; Goossens E; Schepens B; Fiers W; Saelens X J Gen Virol; 2011 Feb; 92(Pt 2):301-6. PubMed ID: 20965983 [TBL] [Abstract][Full Text] [Related]
2. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444 [TBL] [Abstract][Full Text] [Related]
3. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548 [TBL] [Abstract][Full Text] [Related]
4. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706 [TBL] [Abstract][Full Text] [Related]
5. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Liu W; Zou P; Chen YH Immunol Lett; 2004 May; 93(2-3):131-6. PubMed ID: 15158608 [TBL] [Abstract][Full Text] [Related]
7. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Adler-Moore J; Munoz M; Kim H; Romero J; Tumpey T; Zeng H; Petro C; Ernst W; Kosina S; Jimenez G; Fujii G Vaccine; 2011 Jun; 29(27):4460-8. PubMed ID: 21545821 [TBL] [Abstract][Full Text] [Related]
8. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Zhou C; Zhou L; Chen YH Vaccine; 2012 May; 30(23):3463-9. PubMed ID: 22446634 [TBL] [Abstract][Full Text] [Related]
9. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus. Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770 [TBL] [Abstract][Full Text] [Related]
10. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216 [TBL] [Abstract][Full Text] [Related]
11. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin. Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221 [TBL] [Abstract][Full Text] [Related]
12. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine. Jazi MH; Dabaghian M; Tebianian M; Gharagozlou MJ; Ebrahimi SM Virus Res; 2012 Aug; 167(2):219-25. PubMed ID: 22609252 [TBL] [Abstract][Full Text] [Related]
13. Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins. Lee YN; Kim MC; Lee YT; Hwang HS; Lee J; Kim C; Kang SM PLoS One; 2015; 10(9):e0137822. PubMed ID: 26366729 [TBL] [Abstract][Full Text] [Related]
14. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Fan J; Liang X; Horton MS; Perry HC; Citron MP; Heidecker GJ; Fu TM; Joyce J; Przysiecki CT; Keller PM; Garsky VM; Ionescu R; Rippeon Y; Shi L; Chastain MA; Condra JH; Davies ME; Liao J; Emini EA; Shiver JW Vaccine; 2004 Aug; 22(23-24):2993-3003. PubMed ID: 15297047 [TBL] [Abstract][Full Text] [Related]
15. Influenza virus M2e with additional cysteine residues shows enhanced immunogenicity and protection against lethal virus challenge. Kaminaka K; Matsuda J; Nozaki C Viral Immunol; 2013 Aug; 26(4):291-5. PubMed ID: 23941675 [TBL] [Abstract][Full Text] [Related]
16. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Fu TM; Freed DC; Horton MS; Fan J; Citron MP; Joyce JG; Garsky VM; Casimiro DR; Zhao Q; Shiver JW; Liang X Virology; 2009 Mar; 385(1):218-26. PubMed ID: 19070878 [TBL] [Abstract][Full Text] [Related]
17. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses. Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578 [TBL] [Abstract][Full Text] [Related]
19. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. Liu X; Guo J; Han S; Yao L; Chen A; Yang Q; Bo H; Xu P; Yin J; Zhang Z Vaccine; 2012 Oct; 30(46):6527-33. PubMed ID: 22959982 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors. Petukhova NV; Gasanova TV; Stepanova LA; Rusova OA; Potapchuk MV; Korotkov AV; Skurat EV; Tsybalova LM; Kiselev OI; Ivanov PA; Atabekov JG Curr Pharm Des; 2013; 19(31):5587-600. PubMed ID: 23394564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]